Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer

Inokuchi,Mikito; Murayama,Tadao; Hayashi,Mikiko; Takagi,Yoko; Kato,Keiji; Enjoji,Megumu; Kojima,Kazuyuki; Kumagai,Jiro; Sugihara,Kenichi

doi:10.3892/etm.2011.187

Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer

Authors:
- Mikito Inokuchi
- Tadao Murayama
- Mikiko Hayashi
- Yoko Takagi
- Keiji Kato
- Megumu Enjoji
- Kazuyuki Kojima
- Jiro Kumagai
- Kenichi Sugihara
View Affiliations

Affiliations: Department of Surgical Oncology, Tokyo Medical and Dental University, Tokyo 113-8519, Japan, Department of Translational Oncology, Tokyo Medical and Dental University, Tokyo 113-8519, Japan, Department of Esophagogastric Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan, Department of Human Pathology, Tokyo Medical and Dental University, Tokyo 113-8519, Japan
Published online on: January 11, 2011 https://doi.org/10.3892/etm.2011.187
Pages: 251-256

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Signal transducer and activator of transcription 3 (STAT3), the mammalian target of rapamycin (mTOR) and epidermal growth factor receptor (EGFR), proteins that mediate intracellular signaling related to cell growth, proliferation and differentiation, have received considerable interest as possible targets for cancer treatment. We examined whether the expression of STAT3, mTOR and EGFR correlates with clinicopathological features and patient outcome in gastric cancer. Tumor samples were obtained from 126 patients with gastric adenocarcinomas who underwent a radical gastrectomy between 1999 and 2002. The expression of phosphorylated STAT3 (p-STAT3), p-mTOR and EGFR was analyzed by immunohistochemical staining. The relations of these to clinicopathological factors and outcomes were assessed. The expression of p-STAT3 p-mTOR and EGFR positively correlated with the following variables related to tumor progression: the depth of tumor invasion (T1 vs. T2-4; p<0.001, p=0.036 and p<0.001, respectively), lymph node involvement (p=0.008, p=0.027 and p=0.007) and tumor stage (I vs. II-IV; p<0.001, p=0.041 and p<0.001). The expression of p-STAT3 and EGFR was significantly related to distant metastasis and recurrence (p=0.001 and p=0.039), as well as significantly poorer disease-specific survival (DSS; p=0.0018 and p=0.026). The expression of p-STAT3 was a marginally non-significant prognostic factor for DSS (hazard ratio=2.0, 95% CI 0.91-4.5, p=0.082). Increasing expression of p-STAT3, p-mTOR and EGFR was associated with progressively worse DSS. Interactions among p-STAT3, p-mTOR and EGFR may play an important role in tumor progression and outcomes in patients with gastric cancer.

View Figures

View References

1.	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2.	Yonemura Y, Sugiyama K, Fushida S, Kamata T, Ohoyama S, Kimura H, Yamaguchi A and Miyazaki I: Tissue status of epidermal growth factor and its receptor as an indicator of poor prognosis in patients with gastric cancer. Anal Cell Pathol. 3:343–350. 1991.PubMed/NCBI
3.	Hirono Y, Tsugawa K, Fushida S, Ninomiya I, Yonemura Y, Miyazaki I, Endou Y, Tanaka M and Sasaki T: Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology. 52:182–188. 1995. View Article : Google Scholar : PubMed/NCBI
4.	Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW and Heiss MM: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol. 18:2201–2209. 2000.PubMed/NCBI
5.	García I, Vizoso F, Martín A, Sanz L, Abdel-Lah O, Raigoso P and García-Muñiz JL: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 10:234–241. 2003.PubMed/NCBI
6.	Hirashima Y, Yamada Y, Matsubara J, Takahari D, Okita N, Takashima A, Kato K, Hamaguchi T, Shirao K, Shimada Y, Taniguchi H and Shimoda T: Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer. Cancer Sci. 100:310–315. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Jüttner S, Wissmann C, Jöns T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W and Höcker M: Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 24:228–240. 2006.PubMed/NCBI
8.	Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T and Sugihara K: High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res. 14:7843–7849. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Bang YJ, van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J and Kang YK; for the ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar
10.	Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS and Tweardy DJ: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest. 102:1385–1392. 1998. View Article : Google Scholar : PubMed/NCBI
11.	Coffer PJ and Kruijer W: EGF receptor deletions define a region specifically mediating STAT transcription factor activation. Biochem Biophys Res Commun. 210:74–81. 1995. View Article : Google Scholar : PubMed/NCBI
12.	Schmelzle T and Hall MN: TOR, a central controller of cell growth. Cell. 103:253–262. 2000. View Article : Google Scholar : PubMed/NCBI
13.	Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D and Sonenberg N: mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 94:195–199. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T and Sugihara K: Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer. 100:782–788. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene. 15:2474–2488. 2000. View Article : Google Scholar
16.	Levy DE and Lee CK: What does Stat3 do? J Clin Invest. 109:1143–1148. 2002. View Article : Google Scholar : PubMed/NCBI
17.	Yakata Y, Nakayama T, Yoshizaki A, Kusaba T, Inoue K and Sekine I: Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int J Oncol. 30:437–442. 2007.PubMed/NCBI
18.	Kim DY, Cha ST, Ahn DH, Kang HY, Kwon CI, Ko KH, Hwang SG, Park PW, Rim KS and Hong SP: STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol. 24:646–651. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Lee J, Kang WK, Park JO, Park SH, Park YS, Lim HY, Kim J, Kong J, Choi MG, Sohn TS, Noh JH, Bae JM, Kim S, Lim do H, Kim KM and Park CK: Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS. 117:598–606. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol. 58:833–838. 2005. View Article : Google Scholar : PubMed/NCBI
21.	Park JK, Hong R, Kim KJ, Lee TB and Lim SC: Significance of p-STAT3 expression in human colorectal adenocarcinoma. Oncol Rep. 20:597–604. 2008.PubMed/NCBI
22.	Kim HS, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J and Ahn MJ: Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer. 116:676–685. 2010. View Article : Google Scholar
23.	Haura EB, Zheng Z, Song L, Cantor A and Bepler G: Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 11:8288–8294. 2005. View Article : Google Scholar : PubMed/NCBI
24.	Sheen-Chen SM, Huang CC, Tang RP, Chou FF and Eng HL: Prognostic value of signal transducers and activators of transcription 3 in breast cancer. Cancer Epidemiol Biomarkers Prev. 17:2286–2290. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L and Hung MC: Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 3:802–808. 2001. View Article : Google Scholar : PubMed/NCBI
26.	Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih JY and Hung MC: Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell. 7:575–589. 2005. View Article : Google Scholar : PubMed/NCBI
27.	Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A and Martoni AA: Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 101:1261–1268. 2009. View Article : Google Scholar
28.	Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D and Yu D: Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res. 10:6779–6788. 2004. View Article : Google Scholar : PubMed/NCBI
29.	Nam SY, Lee HS, Jung GA, Choi J, Cho SJ, Kim MK, Kim WH and Lee BL: Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. APMIS. 111:1105–1113. 2003. View Article : Google Scholar : PubMed/NCBI
30.	Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG and Javle MM: Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol. 13:933–939. 2006. View Article : Google Scholar : PubMed/NCBI
31.	Ma J, Meng Y, Kwiatkowski DJ, et al: Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest. 120:103–114. 2010. View Article : Google Scholar : PubMed/NCBI